ArticleContemporary oncology (Poznan, Poland)2024
A cohort of long-surviving patients affected by small and medium uveal melanoma treated with ruthenium-106 plaque brachytherapy.
Article in Contemporary oncology (Poznan, Poland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical outcomes of fractionated stereotactic radiotherapy for uveal melanoma - a Polish single-centre experience.Contemporary oncology (Poznan, Poland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study reports the long-term outcomes in patients affected by uveal melanoma (UM) treated with ruthenium-106 ( Material and methods: From May 2005 to January 2024, 127 patients (median age: 69 years, range: 32-90 years) affected by small and medium UM were treated with Results: Inclusion criteria comprised Eastern Cooperative Oncology Group performance status ≤ 2, life expectancy > 6 months, and tumor thickness ≤ 6 mm and/or diameter ≤ 16 mm. The 5-year rate of local control, progression-free survival, metastasis-free survival, and overall survival were 95.2%, 85.4%, 93.0%, and 95.9%, respectively. Local progression was recorded in nine patients (7.1%): two of them (1.6%) had also distant metastasis. Seven patients were retreated with photon beam and one patient with proton beam stereotactic radiosurgery; one patient was retreated with Conclusions: This study suggests that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.